Chemistry:EVT-101
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | ENS-101 |
| Drug class | NMDA receptor antagonist |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H13F3N4 |
| Molar mass | 318.303 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] The drug was first claimed by Roche in 2002.[3] By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.[1]
See also
References
- ↑ 1.0 1.1 1.2 "EVT 101 - AdisInsight". http://adisinsight.springer.com/drugs/800023880.
- ↑ "Archived copy". https://www.evotec.com/uploads/media_library/14/AC_SfN_Poster_2010_FINAL.pdf.
- ↑ "Novel NMDA receptor modulators: an update". Expert Opin Ther Pat 22 (11): 1337–52. 2012. doi:10.1517/13543776.2012.728587. PMID 23009122.
 |  |
